Mankind Pharma Ltd

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 2280.2, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75160.39, down 0.55%.Mankind Pharma Ltd has lost around 6.47% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 1.21 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2290.3, down 0.87% on the day. Mankind Pharma Ltd tumbled 12.59% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.The PE of the stock is 42.12 based on TTM earnings ending June 26.

Mankind Pharma Limited announced the allotment of 49,112 equity shares to eligible employees under its Mankind Employee Stock Option Plan 2022, according to a regulatory filing on September 1, 2026. The shares, with a face value of Rs 1 each, were issued at an exercise price of Rs 860 per share and a premium of Rs 859 per share, increasing the company's paid-up share capital from 41,29,95,978 equity shares to 41,30,45,090 equity shares.

Mankind Pharma Limited informed the BSE Limited and National Stock Exchange of India that Bharat Anand has ceased to be an Independent Director with effect from August 30, 2026, following the completion of his second term, and has also resigned from the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee.

Mankind Pharma Limited announced that its board approved the voluntary liquidation of its 96% owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), with Appian Properties Private Limited, a wholly owned subsidiary of Mankind Pharma, holding the remaining 4% stake. The business of BSVL will be consolidated with Mankind Pharma on a going concern basis, with Appian receiving cash proportionate to its shareholding based on an independent valuation.

Mankind Pharma Limited announced that its board approved the voluntary liquidation of its wholly owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), in which Mankind Pharma holds 96% stake, with the remaining 4% held by Appian Properties Private Limited, also a Mankind Pharma subsidiary. The business of BSVL will be consolidated with Mankind Pharma on a going concern basis, and Appian will receive cash proportionate to its 4% shareholding, as determined by an independent valuer.

Mankind Pharma Limited announced the incorporation of a wholly owned subsidiary, Mankind Pharma (Netherlands) B.V., in the Netherlands on August 13, 2026, as previously disclosed on July 11, 2026, in accordance with Regulations 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mankind Pharma Limited announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. The appointment, recommended by the Nomination and Remuneration Committee, is subject to approval by the company’s members via a postal ballot, for a term of 5 consecutive years. Mr. Bafna, who previously served as Chief Executive Officer and Managing Director of Healthium Medtech Limited, currently serves as Non-Executive Chairman of Healthium and brings over 30 years of experience in the healthcare and medical devices sector.

Mankind Pharma Limited announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. The appointment, recommended by the Nomination and Remuneration Committee, is subject to approval by the company’s members via a postal ballot, for a term of 5 consecutive years. Mr. Bafna, who previously served as Chief Executive Officer and Managing Director of Healthium Medtech Limited, currently serves as Non-Executive Chairman of Healthium and brings over 30 years of experience in the healthcare and medical devices sector.

Mankind Pharma Limited announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. The appointment, recommended by the Nomination and Remuneration Committee, is subject to approval by the company’s members via a postal ballot, for a term of 5 consecutive years. Mr. Bafna, who previously served as Chief Executive Officer and Managing Director of Healthium Medtech Limited, currently serves as Non-Executive Chairman of Healthium and brings over 30 years of experience in the healthcare and medical devices sector.

Mankind Pharma (BSE: 543904 | NSE: MANKIND) announced its financial results for the first quarter ended June 30, 2026, reporting revenue from operations of INR 4,031 crore, a 12.9% year-over-year increase, and a 29.1% rise in profit after tax to INR 574 crore. The company’s EBITDA margin improved to 26.3%, up 250 basis points year-over-year, while its PAT margin increased to 14.2%, up 170 basis points year-over-year, driven by a 11.0% growth in the domestic business (excluding Consumer Health) and a 29.0% increase in exports.